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Abstract
Background: The Asia-specific PLA2G7 994G-T transversion leads to V279F substitution within the lipoprotein-associated
phospholipase-A2 (Lp-PLA2) and to absence of enzyme activity in plasma. This variant offers a unique natural experiment to
assess the role of Lp-PLA2 in the pathogenesis of coronary artery disease (CAD) in humans. Given conflicting results from
mostly small studies, a large two-stage case-control study was warranted.
Methodology/Principal Findings: PLA2G7 V279F genotypes were initially compared in 2890 male cases diagnosed with
CAD before age 60 with 3128 male controls without CAD at age 50 and above and subsequently in a second independent
male dataset of 877 CAD cases and 1230 controls. In the first dataset, the prevalence of the 279F null allele was 11.5% in
cases and 12.8% in controls. After adjustment for age, body mass index, diabetes, smoking, glucose and lipid levels, the OR
(95% CI) for CAD for this allele was 0.80 (0.66–0.97, p=0.02). The results were very similar in the second dataset, despite
lower power, with an allele frequency of 11.2% in cases and 12.5% in controls, leading to a combined OR of 0.80 (0.69–0.92),
p=0.002. The magnitude and direction of this genetic effect were fully consistent with large epidemiological studies on
plasma Lp-PLA2 activity and CAD risk.
Conclusions: Natural deficiency in Lp-PLA2 activity due to carriage of PLA2G7 279F allele protects from CAD in Korean men.
These results provide evidence for a causal relationship between Lp-PLA2 and CAD, and support pharmacological inhibition
of this enzyme as an innovative way to prevent CAD.
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Introduction
Elevated levels of lipoprotein-associated phospholipase A2 (Lp-
PLA2), an enzyme involved in the generation of pro-inflammatory
products in atherosclerotic plaques, have been consistently
associated with an increased risk for coronary artery disease
(CAD) and other vascular diseases in Caucasian and other ethnic
groups, including Koreans. In a recent meta-analysis incorporat-
ing 79036 participants from 32 prospective studies the risk of
developing cardiovascular diseases was increased by 11% for each
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18208standard deviation (SD) unit increase in Lp-PLA2 activity, after
correction for other cardiovascular risk factors [1]. The amplitude
of the association with CAD was comparable to that of non-HDL
cholesterol or systolic blood pressure in these populations. These
epidemiological studies have prompted the discovery of pharma-
cological agents which would inhibit this enzyme and so may
prevent the development of cardiovascular diseases. Such agents
have shown promise in pre-clinical and early clinical development
[2] and are presently in late-stage development [3,4].
A study of Lp-PLA2 activity in Japanese subjects identified a
non-functional (null) V279F allele within the Lp-PLA2–encoding
gene PLA2G7, due to a G to T transversion in exon 9 at position
994 [5]. At least 10 separate reports [5–14] have demonstrated
that homozygous carriers of this variant are lacking the enzyme in
plasma and that heterozygous carriers have around 50% the
activity of individuals carrying two copies of the wild-type allele.
The 279F null allele is relatively frequent in Japan, with
approximately 25% and 2% of the population carrying one or
two copies[6], respectively, and its prevalence shows a declining
gradient towards the West, with intermediate frequencies in China
and Korea[8], rare carriers in the Middle East [15] and almost
complete absence in Europeans. This discovery provides a natural
experiment to gain insight into the causal contribution of Lp-PLA2
to the pathogenesis of CAD, and as such shall complement
epidemiological studies and contribute to our understanding of the
causality of Lp-PLA2 in atherogenesis in humans. Other common
variants within PLA2G7 have been reported, and have minimal, if
any effects on Lp-PLA2 activity as compared to the V279F. In
particular, the most well characterized of those, A379V confers
only a 7.2% difference in Lp-PLA2 activity between AA and VV
homozygotes[16].
Several reports have been published on the association between
the V279F allele and CAD in Asians. An early study in Japanese
subjects showed an increased risk for myocardial infarction (MI)
and stroke in carriers of 279F variant[6,13], whereas a subsequent
study showed only a male- and high cholesterol-specific increased
risk [17] . Others reported no association in either Japanese or
Chinese subjects[7,18]; lastly a decreased risk of CAD was
observed in male carriers of the 279F null allele from Korea [8].
As small sample size (i.e. ,1000 CAD cases) and multiple-testing
issues due to subgroup analyses were likely factors in the disparity
of the results, an appropriately powered study was warranted to
better estimate the effect of the null allele on CAD risk. Here, we
report the results from a two-stage case-control analysis we
performed in men from South Korea. The first dataset (Study 1)
comprised 2890 cases diagnosed with relatively premature CAD
and 3128 controls clinically devoid of the disease. As a positive
control to test for any bias in ascertainment, we used a common
(allele frequency ,50%) single nucleotide polymorphism (SNP)
marker within the 9p21 CDKN2A/B locus which has been robustly
associated with CAD in European [19–21] and in Asian
populations [19,22], including in Korea [23,24]. Recent meta-
analysis of the effect of 9p21 on CAD risk in 22 studies comparing
a total of 35877 cases and 95837 controls showed that carriage of 1
copy of the risk allele is associated with a ,25% increase in the
risk of CAD. [25] The PLA2G7 V279F variant was subsequently
tested within a second, independent group of 877 cases and 1230
controls (Study 2).
Results
A total of 2890 CAD cases and 3128 non-CAD controls were
included in Study 1 (Table 1). Given the design of the study, CAD
cases were younger than controls. As expected and despite their
younger age, cases had a larger BMI and higher levels of glucose
and lipids, with lower HDL-cholesterol levels, and a larger
proportion of them were smokers or diabetic. The majority of
CAD cases were on statins, which may explain the lower levels of
total and LDL-cholesterol. After correction for statin usage, LDL-
cholesterol levels were slightly higher in cases than controls.
Table 1. Characteristics of the participants in Studies 1 and 2.
Study 1 Study 2
Characteristic CAD Control p value* CAD Control p value*
n 2890 3128 877 1230
Age (yrs) 51.166.5 58.466.0 3.5E-267 56.668.2 52.769.0 1.0E-28
BMI (kg/m
2) 25.362.9 24.062.8 6.8E-57 25.162.9 24.262.6 1.8E-11
Glucose (mmol/L) 6.362.4 5.161.1 2.6E-120 5.6961.9 5.0860.67 7.9E-06
Triglycerides (mmol/L) 1.57(0.11–23.5)
{ 1.53(0.34–8.9) 0.03 1.50(0.36–10.8) 1.33(0.17–8.5) 1.8E-07
Total cholesterol (mmol/L) 4.6261.1 4.9460.91 3.9E-35 4.3461.1 5.0760.90 8.6E-54
HDL-cholesterol (mmol/L) 1.0660.26 1.1960.30 5.9E-63 1.1460.30 1.2760.34 7.4E-21
LDL-cholesterol (mmol/L) 2.7460.99 2.9660.86 9.2E-23 2.4360.90 3.0960.85 1.2E-53
Corrected LDL-cholesterol (mmol/L)** 3.1161.2 2.9660.86 0.01 2.7561.02 3.0960.85 1.4E-18
Myocardial Infarction (%) 42% 0% na 46% 0% na
Diabetes (%): Missing n 29%: 208 5%: 85 1.2E-132 29%: 0 0%: 0 1.1E-108
Statin (%): missing n 58%: 385 0.1%: 640 1.0E-267 59%: 4 0.1%: 159 1.4E-227
Smoking (%): missing n 83%: 337 59%: 73 3.6E-89 85%: 3 74%: 2 3.1E-09
Values are mean 6 SD.
{Value is median (minimum - maximum).
**LDL-cholesterol levels were adjusted for the use of statins by multiplying levels by 1.25.
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control for genetic association with CAD. As expected, the risk
allele (G) frequency was significantly higher among CAD cases,
and in the subgroup with MI (Table 2 lower panel). The PLA2G7
279F null allele (Table 2 upper panel) was slightly under-
represented among cases with CAD (11.5%) and MI (11.2%)
compared to controls (12.8%).
Logistic regression analysis was performed to adjust for
differences in various cardiovascular risk factors between the cases
and the controls (Table 3). Smoking, diabetes, BMI, glucose,
triglycerides and HDL-cholesterol levels were significantly associ-
ated with CAD. After inclusion of these covariates into the model,
each copy of the 9p21 locus SNP was associated with an increased
riskof CADof1.28(95% CI 1.16–1.42, p=2.4610
26). Conversely,
the PLA2G7 279F allele was associated with a reduced CAD risk of
0.80 (0.66–0.97, p=0.02), and the effect tended to be gene-dosage
dependent, with an OR 0.79 (0.64–0.98) and 0.69 (0.33–1.44) for
carriers of one and two copies of the 279F allele, respectively. The
protective effect of the null allele was slightly more pronounced for
CAD cases with MI [OR 0.72 (0.56–0.94), p=0.01].
To consolidate these findings, the PLA2G7 V279F variant was
subsequently examined in Study 2, an independent dataset. The
clinical characteristics of the participants in this study were very
similar to the ones observed in Study 1 (Table 1), with the
difference that a less restrictive age criteria was used. The
prevalence of the PLA2G7 279F allele was almost identical in cases
from Studies 1 and 2, and also in controls from these two
independent studies; in particular, the prevalence of 279F in Study
2 was equally lower in cases with CAD (11.2%) and MI (11.3%)
compared to controls (12.5%)(Table 2). In the logistic regression
model, this allele tended to offer a protection against CAD with a
magnitude and direction which were similar to the one observed in
Study 1 [OR 0.80 (0.65–0.98), p=0.04]. If an identical age
criteria to the first study was used in Study 2, despite a smaller
sample size the results were very similar [OR 0.81 (0.62–1.06),
p=0.13], therefore only results from the full sample are presented.
Meta-analysis of the two studies revealed that the 279F null allele
was associated with an overall 20% [OR 0.80 (0.69–0.92),
p=0.002] and 25% reduction [OR 0.75 (0.62–0.90), p=0.002)
in the risk of CAD or MI, respectively (Table 3 and Figure 1). The
association with CAD was not solely dependent on the MI group,
as an analysis of CAD without MI remained significant, OR 0.82
(0.73–0.98), p=0.03.
One potential limitation of this study is the fact that not all cases
and controls were collected from the same sites. In order to assess
heterogeneity between sites, we examined the prevalence of the
279F allele in each site individually. The allele frequency was very
consistent between sites, ranging from 11.3% to 11.8% for CAD
cases and from 12.6% to 13% in controls (Table S1), without any
overlap between the two groups.
Discussion
In this study, the largest to date to explore the association
between the PLA2G7 V279F variant and CAD, we provide
consistent evidence that this null allele offers a significant
protection against CAD, in particular myocardial infarction, in
Korean males.
The present data shows that carriage of one copy of the 279F
null allele was associated with a 20% reduction in risk for CAD.
Our finding is consistent with the expected reduction in CAD risk,
when considered in light of prior reports showing that each allele is
associated with a ,50% reduction in plasma Lp-PLA2 activity [5–
14]. In the meta-analysis by Thompson et al [1], a 50% reduction
in Lp-PLA2 activity/mass corresponded to ,1.5–2.0 SD,
depending on the studies included in the meta-analysis, and each
SD was associated with an 11% reduction in risk of CAD. This is
fully consistent with the estimate of 20% reduction obtained
empirically here. The convergence and consistency of the present
genetic results with the epidemiological data on Lp-PLA2 activity
and CAD risk supports a causative role for Lp-PLA2 in the
generation of CAD.
Taken together, these findings support the use of pharmaco-
logical agents that would inhibit Lp-PLA2 as a way to prevent
CAD. Pharmacological inhibition of the enzyme using darapladib
averages 80%, and therefore the effect may be more pronounced
Table 2. Genotype (n, %) and allele frequencies of V279F (PLA2G7) and RS10757274 (9p21) in Studies 1 and 2.
Study 1 Study 2
CAD MI Control p1 p2 CAD MI Control p1 p2
PLA2G7
VV n(%) 2205(76) 876(77) 2345(75) 0.10
a 0.17
a 692(79) 317(77.9) 933(76) 0.44
a 0.23
a
VF n(%) 564(20) 217(19) 679(22) 174(20) 88(21.6) 264(21)
FF n(%) 40(1) 16(1) 53(2) 11(1) 2(0.5) 20(2)
MAF* (%) 11.5 11.2 12.8 0.03
b 0.10
b 11.2 11.3 12.5 0.21
b 0.37
b
Missing n(%) 81(3) 25(2) 51(1) 0(0) 0(0) 13(1)
9p21
AA n(%) 693(24) 256(23) 979(31) 1.4E-11
a 2.4E-09
a
AG n(%) 1402(49) 556(49) 1485(47)
GG n(%) 698(24) 280(25) 586(19)
MAF* (%) 50.1 51.1 43.6 1.7E-12
b 3.9E-10
b
Missing n(%) 97(3) 42(4) 78(2)
*Minor Allele Frequency. MI: myocardial infarction.
p1: p value for comparison of CAD vs control; p2: p value for comparison of myocardial infarction vs control.
ap value for comparison of genotype frequency;
bp value for comparison of allelic frequency.
doi:10.1371/journal.pone.0018208.t002
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this offers promise for inhibition, it remains challenging to
extrapolate the effect of a genetic defect, established since the
time of conception, to a pharmacological intervention of limited
duration, usually initiated during adult life. As an illustration, for a
similar amplitude, reduction of LDL-cholesterol levels associated
with a genetic variant in PCSK9 appears to provide a stronger
protection against CAD than would statins [26].
The present study has some limitations. First, we only report
here data from men. The PLA2G7 V279F and the 9p21 variants
were originally typed in 1130 female cases (diagnosed before age
65) and 1680 controls (clinically devoid of CAD above age 55)
from Study 1. No association was observed between V279F
mutation and the risk of CAD in this dataset [OR 1.09 (0.85–
1.39), p=0.50]. However, for reasons which were unclear as the
9p21 locus has been equally associated with CAD in males and
females, [21,27] including in Asia [28], no association either was
observed with this positive control [OR 1.11 (0.94–1.30)]. One
possible explanation for these results is the presence of asymp-
tomatic coronary artery disease among control females, and a
corresponding misclassification leading to an absence of detectable
association. In these conditions, and considering the fact that no
women were available in Study 2 to increase power and replicate
findings, it was felt more appropriate, and rigorous, to restrict the
present report to males.
The present study is based on a cross-sectional, age-discordant
case-control design. Because relatively younger CAD cases (who
may have a higher genetic burden than older cases) were
compared with older controls, one cannot exclude the possibility
that the benefits of carrying the 279F allele may have been over-
estimated here. This possibility, however, is unlikely, as similar
ORs were observed in Study 2 which was not age-restricted.
Another limitation of the study is that controls did not have any
coronary angiogram performed on them, and some of them may
have clinically asymptomatic CAD, which may have led to under-
estimation of the effect of the variants tested here. Conversely, the
angiographic case definition for CAD in non-MI individuals was
relatively lenient, and there is a possibility of over-diagnosis of
CAD. Still, the overall amplitude of the effect of the positive
control 9p21 locus marker in the present study (a 28% increase in
CAD risk, Table 3) matched quite closely the effect reported in
other case-control studies performed in Korea [23,24] and a
recent meta-analysis on this marker [25] [OR 1.25 (1.21–1.29)],
suggesting that the amplitude of the protective effect of PLA2G7
279F reported here is quite accurate. Next, in the present study,
cases and controls were not all collected from the same centers.
Table 3. Logistic regression model of CAD and MI in Studies 1 and 2.
Study 1 Study 2
CAD MI CAD MI
Characteristic OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
Smoking 2.85 (2.31–3.51) 7.8E-23 5.52 (3.93–7.77) 1.1E-22 2.15 (1.68–2.75) 1.3E-09 2.68 (1.89–3.79) 2.6E-08
Diabetes* 2.01 (1.36–2.98) 0.0005 2.00 (1.17–3.42) 0.01
BMI (per 1 kg/m
2) 1.06 (1.03–1.10) 0.0005 1.06 (1.01–1.11) 0.01 1.10 (1.06–1.14) 1.9E-07 1.11 (1.06–1.16) 1.2E-05
Glucose (per 1 mmol/L) 1.46 (1.32–1.61) 5.4E-14 1.39 (1.23–1.58) 3.2E-07 1.45 (1.32–1.59) 1.2E-14 1.46 (1.29–1.65) 9.1E-10
Triglycerides (per 1 mmol/L) 0.81 (0.74–0.87) 6.9E-08 0.79 (0.70–0.88) 1.7E-05 1.03 (0.93–1.14) 0.6 1.0 (0.88–1.14) 0.96
HDL-cholesterol (per 1 mmol/L) 0.13 (0.09–0.18) 2.4E-29 0.09 (0.06–0.16) 1.8E-20 0.28 (0.20–0.39) 2.1E-13 0.26 (0.17–0.40) 9.9E-10
PLA2G7 F vs V 0.80 (0.66–0.97) 0.02
a 0.72 (0.56–0.94) 0.01
a 0.80 (0.65–0.98) 0.04
a 0.77 (0.59–1.01) 0.06
a
FF vs VV 0.69 (0.33–1.44) 0.07
b 0.60 (0.22–1.60) 0.05
b 0.63 (0.28–1.42) 0.12
b 0.21 (0.05–0.95) 0.08
b
VF vs VV 0.79 (0.64–0.98) 0.71 (0.53–0.95) 0.81 (0.64–1.02) 0.86 (0.64–1.15)
9p21 G vs A 1.28 (1.16–1.42) 2.4E-06 1.44 (1.22–1.71) 2.5E-05
GG vs AA 1.64 (1.34–2.01) 3.6E-06 2.07 (1.47–2.91) 1.0E-04
GA vs AA 1.14 (0.96–1.35) 1.60 (1.20–2.14)
Meta
CAD MI
Characteristic OR (95% CI) p value OR (95% CI) p value
Smoking 2.53 (2.16–2.97) ,1.0E-25 3.89 (3.05–4.96) ,1.0E-25
Diabetes*
BMI (per 1 kg/m
2) 1.08 (1.05–1.11) 1.11E-09 1.08 (1.04–1.11) 9.4E-07
Glucose (per 1 mmol/L) 1.45 (1.36–1.55) ,1.0E-25 1.43 (1.31–1.56) 1.8E-15
Triglycerides (per 1 mmol/L) 0.88 (0.83–0.94) 8.36E-05 0.87 (0.80–0.95) 0.001
HDL-cholesterol (per 1 mmol/L) 0.20 (0.16–0.26) ,1.0E-25 0.17 (0.12–0.23) ,1.0E-25
PLA2G7 F vs V 0.80 (0.69–0.92) 0.002
a 0.75 (0.62–0.90) 0.002
a
FF vs VV 0.66 (0.38–1.14) 0.05
b 0.43 (0.19–0.96) 0.03
b
VF vs VV 0.72 (0.62–0.84) 0.78 (0.64–0.95)
ap value for comparison of allelic frequency;
bp value for comparison of genotypic frequency. *no estimate in study 2 and meta-analysis, due to zero count in control group.
doi:10.1371/journal.pone.0018208.t003
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the fact that the allele frequencies did not differ markedly between
recruitment centers and the fact that the significance of the results
were not affected upon controlling for genomic control inflation
factor measured in other studies (1.061) [29] are reassuring. If this
inflation factor were applied to our results, the meta-p value
marginally increased (0.0027 vs 0.002) and remained significant.
Finally, Lp-PLA2 levels in plasma were not measured in the
present study. However, given the large, unambiguous body of
published observations, [5–14] one can reliably anticipate that
heterozygous carriage of 279F allele is associated with a ,50%
reduction in activity and homozygosity with almost complete
absence of the enzyme in plasma.
In conclusion, the present study indicates that natural, genetic
deficiency in Lp-PLA2 activity due to carriage of PLA2G7 279F
null allele offers a certain protection against CAD, in particular
MI, in Korean men. As such, these results provide strong evidence
for a causal relationship between Lp-PLA2 and CAD, and
additional support to the concept that pharmacological inhibition
of Lp-PLA2 represents an innovative way to prevent this disease.
Methods
Study Subjects
For Study 1, CAD cases were enrolled in the Seoul National
University Hospital [30], Samsung Medical Center [24] and
Yonsei Cardiovascular Hospital [31]. The diagnosis of CAD was
based on the presence of MI or on angiographic findings. The
diagnosis of MI was made using the World Health Organization
criteria including symptoms, enzyme elevation and electrocardio-
graphic changes. Coronary angiograms were interpreted by a
consensus of two independent observers. CAD was defined as
$50% luminal stenosis in one or more major coronary arteries.
CAD cases were selected among CAD patients diagnosed up to
age 60 years. Patients with the following conditions were excluded
from participation: valvular heart disease, peripheral vascular
disease, significant systemic disease, history of inflammatory
disease and history of congestive heart failure with left ventricular
ejection fraction ,30%. Overall, Seoul National University
Hospital, Samsung Medical Center and Yonsei Cardiovascular
Hospital contributed PLA2G7 V279F genotypes for 943, 526 and
1340 CAD cases, respectively [this genotype was missing for the
remaining 81 cases (2.8%) due to technical reasons, see below]
(Table S1).
Controls for Study 1 were healthy volunteers who participated
in the Seoul National University Hospital genome study (n=281
genotypes) [30], in the Cardiovascular Genome Study (n=667)
[24], in the Korean Health and Genome Study (KoGES,
n=1812) [29] or at the Health Promotion Center in University
Hospitals (n=317) [32], with missing genotypes for 51 individuals
(1.6%). Controls were aged over 50 years and had not been
diagnosed with any cardiovascular diseases at the time of
recruitment. Coronary angiography was not performed on the
controls since they had no evidence of CAD by symptoms, history
or non-invasive testing (electrocardiography). Controls were
studied using the same protocol in each center, including a
standardized interview focusing on medical history, physical
activity, medication, personal habits, a physical examination and
blood testing.
Cases and controls from Study 2 were all recruited from the
Cardiovascular Genomic Center at Yonsei University Medical
Center [31] using a similar inclusion and exclusion criteria, but
with a less restrictive age criteria (age ,80 for cases and .40 years
old for controls). A total of 877 CAD cases (407 MI) and 1230 non-
CAD controls were included in Study 2. All cases and 1217
controls had complete genotype data. If the same age criteria from
Study 1 are applied, there were 686 CAD cases and 701 non-CAD
controls, with complete genotype information.
Written informed consent was obtained from each study
participant, and the study protocol was approved by the ethics
committee or institutional review board in each of the participat-
ing centers (Institutional Review Board of Human Research of
Yonsei University, Institutional Review Board of Seoul National
University Hospital, Samsung Medical Center Ethics Committee,
National Institute of Health Ethics and the Institutional Review
Board of the Korean Health and Genomic Study).
Genotyping
Genomic DNA was prepared from peripheral blood samples
using the Puregene DNA purification kit (Gentra, Minneapolis
MN, USA). SNPs were genotyped using the TaqMan fluorogenic
59 nuclease assay (ABI, Foster City CA, USA). The final volume of
polymerase chain reaction (PCR) was 5 ml, containing 10 ng of
genomic DNA and 2.5 ml TaqMan Universal PCR Master Mix,
with 0.13 ml of 40X Assay Mix (Assay ID C__11915291_20 for
PLA2G7 RS16874954 and C__26505812_10 for 9p21 locus
RS10757274). Thermal cycle conditions were as follows: 50uC
for 2 min, 95uC for 10 min followed by 45 cycles of 95uC for 15 s
and 60uC for 1 min. PCR was performed using a Dual 384-Well
GeneAmp PCR System 9700 (ABI) and the endpoint fluorescent
readings were performed on an ABI PRISM 7900 HT Sequence
Detection System. Duplicate samples (n=212 for V279F and
n=322 for 9p21) and negative controls were included to ensure
genotyping accuracy. The genotyping error rate was 0.2%.
Statistics
Hardy-Weinberg equilibrium was confirmed for both markers
using standard approaches. For Studies 1 and 2, the clinical
characteristics were compared between CAD patients and control
subjects using the chi-square test for categorical variables and 2-
Figure 1. CAD and MI risk (OR and 95% CI) in carriers of the
PLA2G7 279F compared to subjects homozygous for the
common V279 allele are shown by study and combined using
meta-analysis. An additive model was used therefore homozygous
carriers of the 279F would be expected to have twice as much risk
reduction as compared to heterozygous carriers. CAD – coronary artery
disease and MI – myocardial infarction.
doi:10.1371/journal.pone.0018208.g001
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distributed triglycerides levels) for continuous variables. The
association between genotype and CAD was examined using
logistic regression analysis adjusting for age, smoking status
(former and current smoker vs never smoker), BMI, diabetes and
plasma levels of glucose, triglycerides, HDL-cholesterol and LDL-
cholesterol. As a large fraction of CAD cases were taking statins,
LDL-cholesterol levels were corrected as recommended by Tobin
[33] by multiplying LDL-cholesterol levels by a factor of 1.25,
corresponding to a conservative average 20% reduction in LDL-
cholesterol levels in subjects taking statins [34,35]. Since the age
distribution of cases (aged ,60) and controls (aged .50) differed
by design, age was included in the regression model, but the
parameter estimate was not valid. To test for multi-collinearity
between the genotype and covariates which could inflate any
association, we calculated the variance inflation factor (VIF) and
tolerance for all explanatory variables used in the linear regression
analysis. All tolerances were close to.60 and none of the VIFs
exceeded 2.2 in the regression model, providing no evidence of
multi-collinearity. A meta-analysis of the two datasets was
performed to provide an overall statistical evaluation of the effect
of the V279F variant on CAD risk using the inverse variance
weighted average method [36]. Statistical analyses were performed
using SAS v9.0 (SAS Institute Inc, Raleigh NC, USA).
Supporting Information
Table S1 Genotype and allele frequencies of V279F
(PLA2G7) and RS10757274 (9p21) by centers.
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